JP2003513662A
(en)
*
|
1999-11-09 |
2003-04-15 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
15 human secretory proteins
|
WO2001039722A2
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
US6965018B2
(en)
|
2000-06-06 |
2005-11-15 |
Bristol-Myers Squibb Company |
Antibodies directed to B7-related polypeptide, BSL-2
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
DK1436003T3
(en)
*
|
2001-05-24 |
2010-03-15 |
Zymogenetics Inc |
TACI-immunoglobulin fusion proteins
|
RU2596491C2
(en)
|
2005-06-08 |
2016-09-10 |
Дана-Фарбер Кэнсер Инститьют |
Methods and compositions for treating persistent infections
|
EP1976567B1
(en)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
CN102282265B
(en)
|
2008-11-28 |
2020-07-24 |
埃默里大学 |
Methods for treating infectious diseases and tumors
|
JP5971948B2
(en)
|
2008-12-04 |
2016-08-17 |
クルナ・インコーポレーテッド |
Treatment of vascular endothelial growth factor (VEGF) -related diseases by suppression of natural antisense transcripts against VEGF
|
CA2745329C
(en)
|
2008-12-04 |
2022-07-12 |
Opko Curna, Llc |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
ES2637063T3
(en)
|
2008-12-04 |
2017-10-10 |
Curna, Inc. |
Treatment of diseases related to tumor suppressor genes by inhibiting the natural antisense transcript to the gene
|
EP2376535B9
(en)
|
2008-12-09 |
2017-09-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
PL2396038T3
(en)
|
2009-02-12 |
2016-05-31 |
Curna Inc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
JP6066035B2
(en)
*
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
Treatment of glial cell-derived neurotrophic factor (GDNF) -related diseases by suppression of natural antisense transcripts against GDNF
|
MX2011009751A
(en)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
US9155754B2
(en)
|
2009-05-06 |
2015-10-13 |
Curna, Inc. |
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
|
JP5931720B2
(en)
|
2009-05-08 |
2016-06-08 |
クルナ・インコーポレーテッド |
Treatment of dystrophin family-related diseases by suppression of natural antisense transcripts on the DMD family
|
ES2664590T3
(en)
|
2009-05-18 |
2018-04-20 |
Curna, Inc. |
Treatment of diseases related to reprogramming factors by inhibition of the natural antisense transcript to a reprogramming factor
|
CN102549158B
(en)
|
2009-05-22 |
2017-09-26 |
库尔纳公司 |
By suppressing to treat the disease that TFE3 is related to IRS albumen 2 (IRS2) for transcription factor E3 (TFE3) natural antisense transcript
|
US8791085B2
(en)
|
2009-05-28 |
2014-07-29 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
US8921330B2
(en)
|
2009-06-26 |
2014-12-30 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
JP2013500017A
(en)
|
2009-07-24 |
2013-01-07 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT)
|
EP2462229B1
(en)
|
2009-08-05 |
2016-05-11 |
CuRNA, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
CA2770104C
(en)
|
2009-08-11 |
2019-03-19 |
Opko Curna, Llc |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
EP2467482A4
(en)
|
2009-08-21 |
2013-12-11 |
Curna Inc |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
JP6175236B2
(en)
|
2009-09-25 |
2017-08-09 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of FLG-related diseases by modulating the expression and activity of filaggrin (FLG)
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
KR101891352B1
(en)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
ES2657452T3
(en)
|
2009-12-29 |
2018-03-05 |
Curna, Inc. |
Treatment of diseases related to nuclear respiratory factor 1 (NRF1) by inhibition of natural antisense transcript to NRF1
|
RU2611186C2
(en)
|
2009-12-29 |
2017-02-21 |
Курна, Инк. |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
CN102791862B
(en)
|
2009-12-31 |
2017-04-05 |
库尔纳公司 |
IRS2 relevant diseases are treated by suppressing the natural antisense transcript of insulin receptor substrate2 (IRS2) and transcription factor E3 (TFE3)
|
JP5886757B2
(en)
|
2010-01-04 |
2016-03-16 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcripts against interferon regulatory factor 8 (IRF8)
|
CN102822342B
(en)
|
2010-01-06 |
2017-05-10 |
库尔纳公司 |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
NO2529015T3
(en)
|
2010-01-25 |
2018-04-14 |
|
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
WO2011123745A2
(en)
|
2010-04-02 |
2011-10-06 |
Opko Curna Llc |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
CN102858979B
(en)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
FGF21 relevant diseases are treated by suppressing the natural antisense transcript of FGF2 1 (FGF21)
|
CN102933711B
(en)
|
2010-05-03 |
2018-01-02 |
库尔纳公司 |
Sirtuin (SIRT) relevant disease is treated by suppressing the natural antisense transcript of Sirtuin (SIRT)
|
TWI531370B
(en)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
US8980858B2
(en)
|
2010-05-26 |
2015-03-17 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
US9771579B2
(en)
|
2010-06-23 |
2017-09-26 |
Curna, Inc. |
Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
|
EP2593547B1
(en)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
ES2640755T3
(en)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene
|
RU2597972C2
(en)
|
2010-10-22 |
2016-09-20 |
Курна Инк. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
EP2643463B1
(en)
|
2010-11-23 |
2017-09-27 |
CuRNA, Inc. |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
KR102043422B1
(en)
|
2011-06-09 |
2019-11-11 |
큐알엔에이, 인크. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
BR112014005234A2
(en)
|
2011-09-06 |
2017-04-11 |
Curna Inc |
treatment of diseases related to voltage-dependent sodium channel alpha subunits (scnxa) with small molecules
|
TR201815503T4
(en)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Treatment of brain-mediated neurotrophic factor (bknf) related diseases by inhibition of the native antisense transcript to bknf.
|
EA037351B8
(en)
|
2012-05-15 |
2021-04-29 |
Бристол-Майерс Сквибб Компани |
Method of treating cancer using an anti-pd-1 and anti-ctla-4 antibody combination
|